33 research outputs found

    Common metabolic changes in prostate and breast cancer cells following drug treatment.

    No full text
    <p>Quantification of selected metabolites (shown as percent of control, mean ± standard deviation) from MR spectra acquired on prostate (PC3 and LNCaP, N = 8) and breast (MCF-7, N = 3) cancer cell lines following 48 hours of treatment with (A) LY294002 or (B) 17AAG. *: p<0.05; **: p<0.005; ***: p<0.0005. Pcholine: phosphocholine.</p

    Accumulation of citrate following treatment with 17AAG in PC3 prostate cancer cells.

    No full text
    <p>Enlarged section (2.49 – 2.72 ppm) of the MR spectra acquired on polar extracts of PC3 cells following 48 hours of treatment with DMSO (solvent control, black), LY294002 (green) and 17AAG (red). Spectra were normalized according to the probabilistic quotient normalization method.</p

    Multivariate statistical analysis of the MR spectra.

    No full text
    <p>Scores plots (PC1 vs PC2) obtained by performing PCA on the MR spectra acquired on polar extracts (8 replicates per treatment condition) of PC3 and LNCaP prostate cancer cells. Control samples were compared to samples treated for 48 hours with either LY294002 ((A) for PC3 and (C) for LNCaP cells) or 17AAG ((B) for PC3 and (D) for LNCaP cells).</p

    Multivariate statistical analysis of the MR spectra.

    No full text
    <p>Loadings plots (on PC1) obtained by performing the PCA comparisons on the MR spectra of control and one treatment per analysis (as shown in <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0026155#pone-0026155-g003" target="_blank">Fig. 3</a>) acquired on polar extracts of PC3 (black line) and LNCaP (red line) prostate cancer cells following 48 hours of treatment with (A) LY294002 or (B) 17AAG. Enlarged sections of the loadings plots represent the region of 1.9–4.1 ppm. Ala: alanine; Asn: asparagine; Cho: choline; Cit: citrate; Cre: creatine; Fum: fumarate; Glc: glucose; Gln: glutamine; Gly: glycine; GPcho: glycerophosphocholine; GSH: glutathione; His: histidine; Ile: isoleucine; Lac: lactate; Leu: leucine; m-Ino: myo-inositol; Pcho: phosphocholine; Pcre: phosphocreatine; Phe: phenylalanine; Tau: taurine; Tyr: tyrosine; Val: valine, UDPS: UDP sugars.</p

    Inhibition of target signaling pathways in cancer cells following drug treatment.

    No full text
    <p>Schematic of signaling pathways targeted by LY294002 and 17AAG and Western blots showing modulation of p-4E-BP1 and c-Raf (β-actin as loading control) levels following administration of DMSO (solvent control; C), LY294002 (L) or 17AAG (A).</p

    Quantification of CTP:phosphocholine cytidylyltransferase activities.

    No full text
    <p>(A) Buildup of CDP-choline peaks in MCF7 cell lysates over 1.5 hours; (B) Time courses of CDP-choline production in control and SAHA-treated cells, showing no significant change in cytidylyltransferase activity with treatment.</p

    TMZ-induced Chk1 activation is associated with TMZ-induced ALD.

    No full text
    <p>U87 or U87+MGMT cells (A, B) were incubated with TMZ (100 µmol/L, 3 hours), ABT888 (5 µM, continuous), or both (one hr ABT pre-incubation followed by the 3 hr TMZ exposure). Cells were then washed and incubated in drug-free (for TMZ groups) or ABT-containing (for the ABT or ABT+TMZ groups ) media and harvested 1–24 hrs later for analysis of tail moment by single cell alkaline gel electrophoresis (A), or pChk1, Chk1, MGMT, and β-actin expression by Western blot (B). Tail moment values are the mean<u>+</u>standard error for three independent experiments. Similar tail moment and Western blot analyses were performed in G55 cells and G55 cells depleted of MGMT by a one hr pre-exposure to BG (5 µM) 1–24 hrs post TMZ (100 µmol/L, 3 hours) exposure (C). Mean fold induction of protein expression was based on densitometric measurements and is shown (relative to untreated controls) below the relevant immunoreactive bands. *, p<.05.</p

    TMZ-induced Chk1 activation is MMR-independent.

    No full text
    <p>Isogenically paired HCT cells differing only in MMR capabilities (MMR-deficient HCT116 and MMR-proficient HCT3-6) depleted of MGMT by pre-incubation with BG (20 µM, 2 hrs, G55+BG) were incubated with vehicle (U) or TMZ (100 µmol/L, 3 hours) after which TMZ was removed, vehicle or BG was replaced, and cells were harvested at 24–72 hours (A, C) or at earlier time points (1–24 hours, B, D) following TMZ exposure for analysis of H2AX foci (A, DAPI staining in right panel of pairs), DNA content by FACS (B), or pChk1, Chk1, hMLH1, MGMT, and β-actin expression by Western blot (C, D). Mean fold induction of protein expression was based on densitometric measurements and is shown (relative to untreated controls) below the relevant immunoreactive bands. *, p<.05.</p
    corecore